Back to Search Start Over

Red wavelength-induced photobiomodulation enhances indocyanine green-based anticancer photodynamic therapy.

Authors :
Sirek B
Topaloğlu N
Source :
Medical oncology (Northwood, London, England) [Med Oncol] 2024 Nov 19; Vol. 42 (1), pp. 8. Date of Electronic Publication: 2024 Nov 19.
Publication Year :
2024

Abstract

Cancer is a global concern worldwide. Prostate cancer has high prevalence and mortality rates among men. Photodynamic therapy (PDT) is an alternative treatment that is promising and effective with fewer side-effects than conventional therapies. However, some factors may limit its efficacy. For this, PDT can be combined with other modalities such as photobiomodulation (PBM) which is commonly used for increased cell proliferation/differentiation and wound healing. In this study, PBM pre-treatment at 655 nm of wavelength with 1, 3, and 5 J/cm <superscript>2</superscript> energy densities was applied to prostate cancer cells to investigate its role in indocyanine green (ICG)-mediated PDT applications. Following PBM treatment, various analyses were assessed including cell viability, cellular uptake of ICG, ATP production, nitric oxide release, reactive oxygen species generation, and the changes in mitochondrial membrane potential. Increased cell death was observed with the PBM pre-treatment at 1 and 3 J/cm <superscript>2</superscript> energy densities depending on ICG incubation time. Intracellular ROS generation and nitric oxide release by PBM had a significant impact on anticancer PDT action. An enhanced anticancer PDT effect was obtained with the PBM pre-treatment which may become a valuable modality to increase the sensitivity of the cancerous cells to PDT applications.<br />Competing Interests: Declarations Conflict of interest The authors have no competing interest to declare that is relevant to the content of this article. Ethical approval This study does not involve any study with human participants or animals performed by any of the authors. Consent for publication All authors agreed with the content and all gave explicit consent to submit the manuscript for publication.<br /> (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)

Details

Language :
English
ISSN :
1559-131X
Volume :
42
Issue :
1
Database :
MEDLINE
Journal :
Medical oncology (Northwood, London, England)
Publication Type :
Academic Journal
Accession number :
39560842
Full Text :
https://doi.org/10.1007/s12032-024-02558-4